Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This review discusses phytotherapy options for managing benign prostatic hyperplasia, noting some herbal agents show promise in trials for mild-moderate symptoms but more evidence is needed for others.

This systematic review reports that for patients with underlying dermatologic disorders who contracted COVID-19, most experienced mild to moderate exacerbation of their skin conditions and were managed similarly to the general population, suggesting treatment discontinuation during acute infection may prevent severe recurrence.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This study observed that men receiving dutasteride for benign prostatic hyperplasia did not show significant differences in neuropsychological assessments compared to a control group not on dutasteride.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

This article reviews endocrine therapies for androgen excess disorders, emphasizing spironolactone, estrogen, and dexamethasone as effective treatments; it reports no new clinical results.

Researchers observed that dutasteride and finasteride caused structural changes in the penises of both control and hypertensive rats, with dutasteride having a more pronounced effect on the corpus cavernosum.

This study found that KH053, combining Panax ginseng and bee-pollen, significantly reduced prostate weight and DHT levels, inhibiting BPH development in a rat model.

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.

This study found that ethanol extract of Syzygium aromaticum (clove) leaves significantly improved lipid profiles and increased body weight in testosterone-induced benign prostatic hyperplasia rats, suggesting potential anti-hyperlipidemic effects and modulation of body weight through metabolic activity.

In this study, researchers investigated the effects of Aqueous Artocarpus heterophyllus seed extract on testosterone enanthate-induced benign prostatic hyperplasia in adult Wistar rats, using three different dosages to assess its potential as an alternative therapy. Results are not reported in this abstract.

This study examined serum PSA levels in women with androgenetic alopecia to evaluate their potential as a marker for androgen effects on target organs.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

In this study conducted at Sir Ganga Ram Teaching Hospital in Pakistan, researchers found that preoperative use of finasteride significantly reduced intraoperative blood loss and shortened hospital stay for benign prostatic hyperplasia patients undergoing bipolar TURP, compared to those not receiving finasteride.

In a rat model of benign prostatic hyperplasia, this study found that purple corn extract may improve symptoms by inhibiting prostate enlargement, reducing androgen receptor signaling, and exerting anti-inflammatory effects.

This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

This review discusses gender identity disorder in Japan, highlighting the high prevalence and challenges in accessing appropriate treatment, and calls for wider understanding among medical professionals.

The flutamide-loaded hydrogel is a promising, skin-friendly treatment for acne and hair loss, potentially requiring less frequent application.

This case report describes a 13-year-old with DSD raised as female, exhibiting hoarseness and clitoral enlargement, with hormonal assessments not indicating common related deficiencies.

There is no significant link between insulin resistance and certain hair disorders like idiopathic hirsutism and androgenic alopecia.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

This review discusses the etio-pathogenetic factors in benign prostatic hyperplasia and their role in the development of lower urinary tract symptoms but reports no new research findings.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Reduced androgens linked to kinky hair disorder and hair loss; 5a-reductase inhibitors may help.

This study reports that prostatitis, affecting many men aged 30 to 50, arises from diverse causes, including bacterial infections and pelvic pain syndromes, and requires treatment strategies specific to its type, such as antibiotics and lifestyle changes.

The authors discuss BPH treatment options and highlight that while medications can manage symptoms, recent minimally invasive procedures may offer promise for elderly males who are not surgical candidates or wish to avoid surgery.

This thesis explores both environmental and genetic factors in prostate cancer, focusing on surrogate hormone markers, medical radiation, family history, and genetic polymorphisms related to DNA repair and hormone marker genes, but reports no new clinical findings.